Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

Vancomycin remains the mainstay treatment for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) despite increased treatment failures. Daptomycin has been shown to improve clinical outcomes in patients with BSIs caused by MRSA isolates with vancomycin MICs of >1 mg/l...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Antimicrob Agents Chemother
Egile Nagusiak: Claeys, Kimberly C., Zasowski, Evan J., Casapao, Anthony M., Lagnf, Abdalhamid M., Nagel, Jerod L., Nguyen, Cynthia T., Hallesy, Jessica A., Compton, Mathew T., Kaye, Keith S., Levine, Donald P., Davis, Susan L., Rybak, Michael J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2016
Gaiak:
Clinical Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038271/
https://ncbi.nlm.nih.gov/pubmed/27431221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00227-16
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak